Molecular pathways of angiogenesis inhibition.

Angiogenesis Inhibitors/therapeutic use; Angiostatins/therapeutic use; Apoptosis/drug effects; Autoantigens/therapeutic use; Cell Cycle/drug effects; Cell Division/drug effects; Cell Survival/drug effects; Collagen Type IV/therapeutic use; Endostatins/therapeutic use; Humans; Matrix Metalloproteinase 2/antagonists & inhibitors; Neovascularization, Pathologic/prevention & control; Platelet Factor 4/therapeutic use; Thrombospondin 1/therapeutic use

Abstract :

[en] A large body of evidence now demonstrates that angiostatic therapy represents a promising way to fight cancer. This research recently resulted in the approval of the first angiostatic agent for clinical treatment of cancer. Progress has been achieved in decrypting the cellular signaling in endothelial cells induced by angiostatic agents. These agents predominantly interfere with the molecular pathways involved in migration, proliferation and endothelial cell survival. In the current review, these pathways are discussed. A thorough understanding of the mechanism of action of angiostatic agents is required to develop efficient anti-tumor therapies.

Disciplines :

Biochemistry, biophysics & molecular biology

Author, co-author :

Tabruyn, Sébastien ; Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire

Griffioen, Arjan W

Language :

English

Title :

Molecular pathways of angiogenesis inhibition.

Publication date :

2007

Journal title :

Biochemical and Biophysical Research Communications

ISSN :

0006-291X

eISSN :

1090-2104

Publisher :

Academic Press, San Diego, United States - California

Volume :

355

Issue :

Pages :

1-5

Peer reviewed :

Peer reviewed

Available on ORBi :

since 26 November 2010

Statistics

Number of views

79 (8 by ULiège)

Number of downloads

2 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438 (2005) 932-936
Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285 (1971) 1182-1186
O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., and Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
Rehn M., Veikkola T., Kukk-Valdre E., Nakamura H., Ilmonen M., Lombardo C., Pihlajaniemi T., Alitalo K., and Vuori K. Interaction of endostatin with integrins implicated in angiogenesis. Proc. Natl. Acad. Sci. USA 98 (2001) 1024-1029
Karumanchi S.A., Jha V., Ramchandran R., Karihaloo A., Tsiokas L., Chan B., Dhanabal M., Hanai J.I., Venkataraman G., Shriver Z., Keiser N., Kalluri R., Zeng H., Mukhopadhyay D., Chen R.L., Lander A.D., Hagihara K., Yamaguchi Y., Sasisekharan R., Cantley L., and Sukhatme V.P. Cell surface glypicans are low-affinity endostatin receptors. Mol. Cell 7 (2001) 811-822
Kim Y.M., Hwang S., Kim Y.M., Pyun B.J., Kim T.Y., Lee S.T., Gho Y.S., and Kwon Y.G. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J. Biol. Chem. 277 (2002) 27872-27879
Lee S.J., Jang J.W., Kim Y.M., Lee H.I., Jeon J.Y., Kwon Y.G., and Lee S.T. Endostatin binds to the catalytic domain of matrix metalloproteinase-2. FEBS Lett. 519 (2002) 147-152
Dixelius J., Cross M., Matsumoto T., Sasaki T., Timpl R., and Claesson-Welsh L. Endostatin regulates endothelial cell adhesion and cytoskeletal organization. Cancer Res. 62 (2002) 1944-1947
Hanai J., Dhanabal M., Karumanchi S.A., Albanese C., Waterman M., Chan B., Ramchandran R., Pestell R., and Sukhatme V.P. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J. Biol. Chem. 277 (2002) 16464-16469
Shichiri M., and Hirata Y. Antiangiogenesis signals by endostatin. FASEB J. 15 (2001) 1044-1053
Kang H.Y., Shim D., Kang S.S., Chang S.I., and Kim H.Y. Protein kinase B inhibits endostatin-induced apoptosis in HUVECs. J. Biochem. Mol. Biol. 39 (2006) 97-104
Dhanabal M., Ramchandran R., Waterman M.J., Lu H., Knebelmann B., Segal M., and Sukhatme V.P. Endostatin induces endothelial cell apoptosis. J. Biol. Chem. 274 (1999) 11721-11726
Hamano Y., and Kalluri R. Tumstatin, the NC1 domain of alpha3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth. Biochem. Biophys. Res. Commun. 333 (2005) 292-298
Maeshima Y., Colorado P.C., and Kalluri R. Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J. Biol. Chem. 275 (2000) 23745-23750
Sudhakar A., Sugimoto H., Yang C., Lively J., Zeisberg M., and Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc. Natl. Acad. Sci. USA 100 (2003) 4766-4771
Wahl M.L., Kenan D.J., Gonzalez-Gronow M., and Pizzo S.V. Angiostatin's molecular mechanism: aspects of specificity and regulation elucidated. J. Cell Biochem. 96 (2005) 242-261
Veitonmaki N., Cao R., Wu L.H., Moser T.L., Li B., Pizzo S.V., Zhivotovsky B., and Cao Y. Endothelial cell surface ATP synthase-triggered caspase-apoptotic pathway is essential for k1-5-induced antiangiogenesis. Cancer Res. 64 (2004) 3679-3686
Troyanovsky B., Levchenko T., Mansson G., Matvijenko O., and Holmgren L. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J. Cell Biol. 152 (2001) 1247-1254
Sharma M.R., Tuszynski G.P., and Sharma M.C. Angiostatin-induced inhibition of endothelial cell proliferation/apoptosis is associated with the down-regulation of cell cycle regulatory protein cdk5. J. Cell Biochem. 91 (2004) 398-409
Chen Y.H., Wu H.L., Li C., Huang Y.H., Chiang C.W., Wu M.P., and Wu L.W. Anti-angiogenesis mediated by angiostatin K1-3, K1-4 and K1-4.5. Involvement of p53, FasL, AKT and mRNA deregulation. Thromb. Haemost. 95 (2006) 668-677
Gupta N., Nodzenski E., Khodarev N.N., Yu J., Khorasani L., Beckett M.A., Kufe D.W., and Weichselbaum R.R. Angiostatin effects on endothelial cells mediated by ceramide and RhoA. EMBO Rep. 2 (2001) 536-540
Hari D., Beckett M.A., Sukhatme V.P., Dhanabal M., Nodzenski E., Lu H., Mauceri H.J., Kufe D.W., and Weichselbaum R.R. Angiostatin induces mitotic cell death of proliferating endothelial cells. Mol. Cell Biol. Res. Commun. 3 (2000) 277-282
Abdollahi A., Hahnfeldt P., Maercker C., Grone H.J., Debus J., Ansorge W., Folkman J., Hlatky L., and Huber P.E. Endostatin's antiangiogenic signaling network. Mol. Cell 13 (2004) 649-663
Good D.J., Polverini P.J., Rastinejad F., Le Beau M.M., Lemons R.S., Frazier W.A., and Bouck N.P. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. USA 87 (1990) 6624-6628
Armstrong L.C., and Bornstein P. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol. 22 (2003) 63-71
Dawson D.W., Pearce S.F., Zhong R., Silverstein R.L., Frazier W.A., and Bouck N.P. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J. Cell Biol. 138 (1997) 707-717
Jimenez B., Volpert O.V., Crawford S.E., Febbraio M., Silverstein R.L., and Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat. Med. 6 (2000) 41-48
Short S.M., Derrien A., Narsimhan R.P., Lawler J., Ingber D.E., and Zetter B.R. Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J. Cell Biol. 168 (2005) 643-653
Lawler J., Weinstein R., and Hynes R.O. Cell attachment to thrombospondin: the role of ARG-GLY-ASP, calcium, and integrin receptors. J. Cell Biol. 107 (1988) 2351-2361
Nor J.E., Mitra R.S., Sutorik M.M., Mooney D.J., Castle V.P., and Polverini P.J. Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. J. Vasc. Res. 37 (2000) 209-218
Volpert O.V. Modulation of endothelial cell survival by an inhibitor of angiogenesis thrombospondin-1: a dynamic balance. Cancer Metastasis Rev. 19 (2000) 87-92
Bikfalvi A. Platelet factor 4: an inhibitor of angiogenesis. Semin. Thromb. Hemost. 30 (2004) 379-385
Klein-Soyer C., Duhamel-Clerin E., Ravanat C., Orvain C., Lanza F., and Cazenave J.P. PF4 inhibits thrombin-stimulated MMP-1 and MMP-3 metalloproteinase expression in human vascular endothelial cells. C R Acad. Sci. III 320 (1997) 857-868
Gentilini G., Kirschbaum N.E., Augustine J.A., Aster R.H., and Visentin G.P. Inhibition of human umbilical vein endothelial cell proliferation by the CXC chemokine, platelet factor 4 (PF4), is associated with impaired downregulation of p21(Cip1/WAF1). Blood 93 (1999) 25-33
Yu G., Rux A.H., Ma P., Bdeir K., and Sachais B.S. Endothelial expression of E-selectin is induced by the platelet-specific chemokine platelet factor 4 through LRP in an NF-kappaB-dependent manner. Blood 105 (2005) 3545-3551
Mayo K.H., van der Schaft D.W., and Griffioen A.W. Designed beta-sheet peptides that inhibit proliferation and induce apoptosis in endothelial cells. Angiogenesis 4 (2001) 45-51
van der Schaft D.W., Dings R.P., de Lussanet Q.G., van Eijk L.I., Nap A.W., Beets-Tan R.G., Bouma-Ter Steege J.C., Wagstaff J., Mayo K.H., and Griffioen A.W. The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB J. 16 (2002) 1991-1993
Brandwijk R.J., Dings R.P., van der Linden E., Mayo K.H., Thijssen V.L., and Griffioen A.W. Anti-angiogenesis and anti-tumor activity of recombinant anginex. Biochem. Biophys. Res. Commun. 349 (2006) 1073-1078
Pilch J., Franzin C.M., Knowles L.M., Ferrer F.J., Marassi F.M., and Ruoslahti E. The anti-angiogenic peptide anginex disrupts the cell membrane. J. Mol. Biol. 356 (2006) 876-885
Thijssen V.L., Postel R., Brandwijk R.J., Dings R.P., Nesmelova I., Satijn S., Verhofstad N., Nakabeppu Y., Baum L.G., Bakkers J., Mayo K.H., Poirier F., and Griffioen A.W. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc. Natl. Acad. Sci. USA 103 (2006) 15975-15980
Ferrara N., Clapp C., and Weiner R. The 16 K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology 129 (1991) 896-900
Nguyen N.Q., Tabruyn S.P., Lins L., Lion M., Cornet A.M., Lair F., Rentier-Delrue F., Brasseur R., Martial J.A., and Struman I. Prolactin/growth hormone-derived antiangiogenic peptides highlight a potential role of tilted peptides in angiogenesis. Proc. Natl. Acad. Sci. USA 103 (2006) 14319-14324
Brasseur R. Tilted peptides: a motif for membrane destabilization (hypothesis). Mol. Membrane Biol. 17 (2000) 31-40
Castellino F.J., and Ploplis V.A. Structure and function of the plasminogen/plasmin system. Thromb. Haemost. 93 (2005) 647-654
Lee H., Struman I., Clapp C., Martial J., and Weiner R.I. Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expression. Endocrinology 139 (1998) 3696-3703
Tabruyn S.P., Nguyen N.Q., Cornet A.M., Martial J.A., and Struman I. The antiangiogenic factor, 16-kDa human prolactin, induces endothelial cell cycle arrest by acting at both the G0-G1 and the G2-M phases. Mol. Endocrinol. 19 (2005) 1932-1942
D'Angelo G., Martini J.F., Iiri T., Fantl W.J., Martial J., and Weiner R.I. 16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells. Mol. Endocrinol. 13 (1999) 692-704
Martini J.F., Piot C., Humeau L.M., Struman I., Martial J.A., and Weiner R.I. The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation. Mol. Endocrinol. 14 (2000) 1536-1549
Tabruyn S.P., Sorlet C.M., Rentier-Delrue F., Bours V., Weiner R.I., Martial J.A., and Struman I. The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-kappaB. Mol. Endocrinol. 17 (2003) 1815-1823
Kisseleva T., Song L., Vorontchikhina M., Feirt N., Kitajewski J., and Schindler C. NF-kappaB regulation of endothelial cell function during LPS-induced toxemia and cancer. J. Clin. Invest. 116 (2006) 2955-2963
Dirkx A.E., oude Egbrink M.G., Castermans K., van der Schaft D.W., Thijssen V.L., Dings R.P., Kwee L., Mayo K.H., Wagstaff J., Bouma-ter Steege J.C., and Griffioen A.W. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J. 20 (2006) 621-630